Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and three have issued a strong buy recommendation on the company.
Separately, Chardan Capital upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
